Big Money Sentiment increased to 1.52 in Q2 2018. It has change of 0.50, from 2018Q1’s 1.02. The ratio is positive due to JAZZ positioning: 25 sold and 88 reduced. 79 funds amassed positions and 93 increased positions. Investors holded 51.95 million in 2018Q1 but now own 54.43 million shares or 4.78% more. Employees Retirement Association Of Colorado invested in 0.01% or 11,872 shs. Bridges owns 1,465 shs. Fmr Limited Liability Co, Massachusetts-based fund reported 6.63 million shs. Ls Advisors reported 773 shs. Rock Springs LP invested in 98,000 shs. California State Teachers Retirement has 91,992 shs. Epoch Inv Prtn Inc has 0.09% invested in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). State Of Alaska Department Of Revenue reported 0.02% stake. Brave Asset Mgmt reported 0.17% stake. Parametric Port Limited Liability Corporation accumulated 0.01% or 64,449 shs. Segall Bryant And Hamill Limited has 0.01% invested in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). 10,800 are owned by Utah Retirement Sys. Reilly Fincl Advsrs Ltd Llc holds 0% or 23 shs. Meiji Yasuda Life Company invested in 0.08% or 3,410 shs. Huntington Commercial Bank reported 0% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ).
JAZZ had 15 insider sales and 0 insider buys since May 11, 2018. This’s net activity of $5.01 million. WILSON KAREN J had sold 3,760 shs worth $620,400. On Thursday, August 9 Shares for $116,563 were sold by O’Keefe Kenneth W. On Monday, May 14 MILLER MICHAEL PATRICK also sold $32,936 worth of Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Shares for $273,296 were sold by COZADD BRUCE C. ENRIGHT PATRICK G had sold 10,130 shs worth $1.71 million. Gray Peter had sold 715 shs worth $126,277 on Thursday, August 9.
Based on the latest 2018Q2 regulatory filing with the SEC, Partner Fund Management Lp upped its holdings in Jazz Pharmaceuticals Plc (JAZZ) by 9.1%. The company’s stock declined 5.67% while stock markets rallied as Partner Fund Management Lp bought 103,379 shares. The major pharmaceuticals company announced $213.46M value for the 2018Q2. Now the hedge fund is holding 1.24 million shares, compared to the 1.14 million from the previous quarter. $8.79 billion is Jazz Pharmaceuticals Plc’s market cap. JAZZ touched $145.57 during the last trading session after $3.38 change.Jazz Pharmaceuticals plc is uptrending after having risen 6.65% since November 10, 2017. JAZZ has 1.05 million volume or 102.10% up from normal. JAZZ underperformed by 8.97% the S&P 500.
According to a filing the Partner Fund Management Lp’s stake in Davita Inc (Call) (NYSE:DVA) was reduced by 204,603 shares to 420,400 shares valued at $29.19M in 2018Q2. It manages about $6.39B US Long portfolio. For a total of 156,000 shares it reduced its holding in Alibaba Group Hldg Ltd (Call) (NYSE:BABA) by 123,501 shares in the quarter, and has cut its stake in Cme Group Inc (NASDAQ:CME).
For more Jazz Pharmaceuticals plc (NASDAQ:JAZZ) news announced recently go to: Seekingalpha.com, Seekingalpha.com, Seekingalpha.com, Streetinsider.com or Nasdaq.com. The titles are as follows: “Jazz Pharma files marketing application in Europe for solriamfetol for narcolepsy/sleep apnea” announced on November 09, 2018, “FDA OKs expanded use for Jazz Pharma’s Xyrem” on October 29, 2018, “Jazz Pharmaceuticals beats by $0.26, misses on revenue” with a publish date: November 06, 2018, “Jazz Pharmaceuticals (JAZZ) PT Lowered to $203 at BMO Capital” and the last “Why Jazz Pharmaceuticals plc Stock Is Slumping Today” with publication date: November 07, 2018.
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Ratings Coverage
In total 6 analysts cover Jazz Pharmaceuticals (NASDAQ:JAZZ). “Buy” rating has 5, “Sell” are 0, while 1 are “Hold”. 83% are bullish. 7 are the (NASDAQ:JAZZ)’s analyst reports since June 1, 2018 according to StockzIntelligence Inc. The stock rating was maintained by FBR Capital with “Buy” on Monday, June 25. On Tuesday, July 10 the stock has “Buy” rating by Citigroup. The stock rating was maintained by RBC Capital Markets with “Buy” on Friday, June 1. On Wednesday, August 8 the rating was maintained by Stifel Nicolaus with “Buy”. In Wednesday, August 8 report BMO Capital Markets maintained the stock with “Outperform” rating. On Wednesday, July 11 the stock has “Equal-Weight” rating by Morgan Stanley. On Thursday, November 8 the firm earned “Buy” rating by FBR Capital.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.